Biotech News

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences (COGT)Cogent BiosciencesClinical readout

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for AdvSM patients APEX NDA is third submission for bezuclastinib in six months; PEAK

Related news

MGNXMacroGenics2026-10-26 11:06 EST

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

BMYBMYBristol-Myers Squibb Company2026-10-25 07:30 EST

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

JNJJohnson & Johnson2026-10-24 13:01 EST

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer

BMYBMYBristol-Myers Squibb Company2026-10-23 11:30 EST

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

RVMDRevolution Medicines2026-11-19 23:05 EST

Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026

REGNRegeneron Pharmaceuticals2026-11-19 12:00 EST

Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

Cogent Biosciences

Genetically Defined Diseases Cogent Biosciences develops precision therapies for diseases driven by defined oncogenic mutations. Its portfolio is led by a selective KIT inhibitor and includes earlier programs directed at ErbB2, PI3Kα, KRAS and JAK2. Bezuclastinib Bezuclastinib is designed to inhibit KIT D816V and other exon 17 KIT...

Recent company news

Stock data

Close
27.74 USD
Market cap
5.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States